The field of senotherapeutics rests on a single strategic fork: senescent cells accumulate in tissues with age and contribute to disease, and researchers must decide whether to kill those cells outright or leave them alive but defanged. Senolytics take the first path, selectively inducing apoptosis in senescent cells. Senomorphics take the second, suppressing the harmful inflammatory secretions those cells produce without eliminating them. Both remain firmly experimental, with translation to humans still in early stages despite encouraging animal data.

Understanding Cellular Senescence: The Root of Age-Related Diseases

Cellular senescence is defined in the research literature as an irreversible arrest of cell division in response to stress or damage. It begins as a protective mechanism: by stopping replication, a senescent cell prevents damaged genetic material from propagating. The trouble is what happens next. Over time, senescent cells accumulate in tissues, and reviews of aging biology link this accumulation to declining cellular function and a range of age-related conditions, including cardiovascular diseases, neurodegenerative disorders, and cancers.

Part of the damage comes from what senescent cells secrete. Their presence is often accompanied by the senescence-associated secretory phenotype (SASP), a pro-inflammatory state that can exacerbate tissue dysfunction and promote chronic disease progression. Yet the SASP is not uniformly harmful. One review notes that it can exert both pro-inflammatory and immunosuppressive effects depending on cell type, tissue context, and timing — in early stages it may even be profibrotic and immunomodulatory. That context-dependence is central to why researchers disagree about the best way to intervene.